Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M. Schürrle SB, et al. Among authors: navalkissoor s. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2428-2441. doi: 10.1007/s00259-024-06682-1. Epub 2024 Mar 26. Eur J Nucl Med Mol Imaging. 2024. PMID: 38528164 Free PMC article. Clinical Trial.
Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.
Clement D, Navalkissoor S, Srirajaskanthan R, Courbon F, Dierickx L, Eccles A, Lewington V, Mitjavila M, Percovich JC, Lequoy B, He B, Folitar I, Ramage J. Clement D, et al. Among authors: navalkissoor s. Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3529-3537. doi: 10.1007/s00259-022-05771-3. Epub 2022 Apr 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 35389069 Free PMC article.
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ. Wild D, et al. Among authors: navalkissoor s. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):183-195. doi: 10.1007/s00259-023-06383-1. Epub 2023 Sep 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721581 Free PMC article. Clinical Trial.
63 results